Skip to main content

Alecnib 150 mg ( Alectinib)

Alecnib 150 mg is identified on this website as a medicine containing alectinib, a targeted anticancer active ingredient. Alectinib is an anaplastic lymphoma kinase (ALK) inhibitor used in the treatment of certain patients with ALK-positive NSCLC.

The stated strength of Alecnib is 150 mg. Product-specific details, including its manufacturer, dosage form, regulatory status, and approved instructions, should be confirmed from the original packaging and applicable product documentation.

Alectinib is used to treat specific forms of ALK-positive non-small cell lung cancer. Depending on the applicable country's approved prescribing information, it may be used in certain patients with ALK-positive NSCLC that has spread to other parts of the body or as treatment following surgery in eligible patients.

It is not a general treatment for every type of lung cancer. The presence of an ALK alteration must be established using an appropriate diagnostic test.

ALK-positive lung cancer is a type of cancer in which the tumor contains a specific genetic alteration involving the anaplastic lymphoma kinase gene.

This alteration can produce abnormal ALK signaling that contributes to cancer cell growth and survival. Medicines such as alectinib are designed to block this signaling pathway.

A healthcare professional may recommend molecular testing of tumor tissue or another appropriate sample to determine whether a patient's cancer is ALK-positive.

Alectinib works by inhibiting abnormal ALK signaling inside cancer cells. In ALK-positive lung cancer, changes involving the ALK gene can produce signals that encourage cancer cells to grow and multiply.

By blocking the activity of the abnormal ALK protein, alectinib can interfere with these signals and help control cancer growth.

Alectinib can also reach the central nervous system, which is relevant because ALK-positive lung cancer may spread to the brain. However, treatment response varies, and its use does not guarantee that brain metastases will disappear or remain controlled.

Alectinib is generally classified as a targeted therapy rather than conventional chemotherapy.

Traditional chemotherapy medicines commonly affect rapidly dividing cells through different mechanisms. Alectinib specifically targets abnormal ALK signaling in cancer cells.

Although targeted therapies work differently from conventional chemotherapy, they can still cause significant side effects and require medical supervision.

For the reference product Alecensa, the recommended adult dose in the United States prescribing information is 600 mg twice daily with food.

When using the reference product's 150 mg capsules, this corresponds to four capsules per dose, taken twice daily.

This is reference-product information and should not be treated as an individualized prescription or automatic dosing instruction for Alecnib. The correct regimen must be confirmed by the treating oncologist and the applicable product documentation.

The reference alectinib product Alecensa is taken with food. Patients prescribed this formulation should follow the food instructions in its official prescribing information.

Food requirements may be important for consistent medicine administration. Patients should not change how they take their medicine without checking with their healthcare professional.

The standard adult regimen for the reference Alecensa product is twice daily. Patients generally take one dose in the morning and another in the evening, according to their prescribed schedule.

The exact number of capsules and timing must follow the patient's prescription. Patients should not take additional doses if they forget a scheduled dose.

The reference Alecensa formulation should be taken with food. Patients should follow the instructions provided for their specific medicine rather than assuming that it can be taken on an empty stomach.

If nausea, appetite loss, or another problem makes it difficult to eat, patients should discuss the issue with their oncology team.

For the reference Alecensa product, if a dose is missed, the next dose should be taken at the regularly scheduled time. Patients should not take an extra dose to make up for the missed one.

Taking two doses together may increase the risk of adverse effects. Patients who frequently miss doses should discuss ways to maintain a consistent treatment routine with their healthcare professional.

According to the reference Alecensa instructions, patients should not take an additional dose to replace a dose after vomiting.

The next dose should be taken at the regularly scheduled time. Repeated or severe vomiting should be reported to the healthcare team, particularly if the patient cannot maintain adequate food or fluid intake.

Possible side effects of alectinib include:

  • Tiredness or fatigue.
  • Constipation.
  • Swelling in the hands, feet, or other areas.
  • Muscle pain or tenderness.
  • Nausea.
  • Changes in liver enzyme levels.
  • Changes in blood test results.

Not every patient experiences these effects. Their severity can vary depending on individual health, treatment duration, and other medicines being used.

Patients should report persistent, worsening, or troublesome symptoms to their healthcare professional.

Yes. Although not every patient experiences serious complications, alectinib can cause potentially severe adverse reactions.

Important risks include:

  • Liver injury: May involve abnormal liver tests, yellowing of the skin or eyes, dark urine, or unusual tiredness.
  • Interstitial lung disease or pneumonitis: May cause new or worsening cough, breathing difficulty, or fever.
  • Bradycardia: Alectinib may slow the heart rate and cause dizziness, fainting, or weakness.
  • Muscle injury: Muscle pain, tenderness, or weakness may be associated with increased CPK levels.
  • Hemolytic anemia: Red blood cells may break down faster than normal.
  • Kidney problems: Kidney function may be affected in some patients.

Patients should seek prompt medical assessment if they develop concerning symptoms. Severe breathing difficulty, fainting, or other signs of a medical emergency require urgent attention.

Alectinib can cause liver enzyme abnormalities and, in some cases, serious liver injury.

Healthcare professionals usually arrange liver function tests before and during treatment. The reference Alecensa prescribing information recommends testing every two weeks during the first three months, followed by monthly testing and additional monitoring when clinically indicated.

Patients should report symptoms such as yellowing of the skin or eyes, dark urine, abdominal discomfort, or unusual fatigue.

Yes. Muscle pain, tenderness, or weakness can occur during alectinib treatment. In some patients, these symptoms may be associated with increased creatine phosphokinase (CPK), a marker that can indicate muscle injury.

Patients should report unexplained muscle symptoms rather than assuming they are ordinary treatment discomfort.

The healthcare professional may arrange CPK blood tests and decide whether treatment modification is necessary.

Alectinib can penetrate the central nervous system and is used in the treatment of certain patients with ALK-positive NSCLC, including patients whose disease involves the brain, according to applicable indications.

Its ability to reach the central nervous system is an important feature of the medicine. However, individual treatment response is not guaranteed.

Patients with brain metastases require ongoing assessment by their oncology team. The appropriate treatment plan depends on the location and extent of the disease, symptoms, previous treatment, and overall clinical condition.

Treatment duration depends on the reason alectinib is prescribed and how the patient responds.

For metastatic ALK-positive NSCLC, the reference Alecensa prescribing information generally recommends continuing treatment until disease progression or unacceptable toxicity.

In the United States, the reference product's adjuvant indication after surgery specifies treatment for two years or until disease recurrence or unacceptable toxicity, as applicable.

These treatment-duration details are specific to the reference product's prescribing information. Patients should follow their own oncologist's plan and should not stop treatment simply because they feel better.

Alectinib may interact with other medicines. Some drugs can affect how medicines are metabolized or transported in the body, potentially changing their effects or the risk of adverse reactions.

Patients should tell their healthcare professional about all products they use, including:

  • Prescription medicines.
  • Non-prescription medicines.
  • Vitamins and minerals.
  • Herbal products.
  • Other cancer treatments.

Patients should not start, stop, or change another medicine without discussing it with their doctor or pharmacist.

Alectinib may cause harm to an unborn baby. Patients who are pregnant, planning pregnancy, or who could become pregnant should discuss the risks with their healthcare professional before starting treatment.

Appropriate pregnancy testing and effective contraception may be required according to the applicable prescribing information.

The recommended contraception period during and after treatment depends on the product label. Patients should obtain the exact instructions from their oncologist rather than relying on a general timeframe.

Breastfeeding is not recommended during treatment with the reference alectinib product under its United States prescribing information.

Patients who are breastfeeding or considering breastfeeding should discuss the risks and appropriate timing with their healthcare professional. They should follow the applicable product information for any restrictions after treatment ends.

Yes. Regular monitoring is important because alectinib may affect the liver, muscles, and other parts of the body.

Depending on the patient's circumstances, monitoring may include:

  • Liver function tests.
  • CPK levels.
  • Kidney function tests.
  • Blood counts when clinically indicated.
  • Heart rate assessment.
  • Evaluation of new respiratory or muscle symptoms.

The timing and frequency of tests should be determined by the treating healthcare professional.

Alectinib is intended for specific patients with ALK-positive NSCLC. It should not be used without a confirmed diagnosis and a prescription from an appropriate healthcare professional.

Patients should discuss their medical history before treatment, particularly if they have:

  • Liver disease.
  • Kidney problems.
  • A slow heart rate or heart rhythm condition.
  • Previous serious muscle problems.
  • A history of lung inflammation.
  • Pregnancy or plans to become pregnant.
  • Current breastfeeding.

These conditions do not automatically mean every patient must avoid alectinib. The treating oncologist must assess the potential benefits and risks.

Yes. A healthcare professional may reduce the dose or temporarily interrupt treatment if certain adverse reactions occur.

Dose adjustments depend on the type and severity of the reaction, laboratory results, and the applicable prescribing information.

Patients should never reduce the number of capsules or change the treatment schedule independently.

Taking more alectinib than prescribed may increase the risk of adverse reactions. Anyone who has taken an excessive amount should contact a healthcare professional or local poison information service immediately for advice.

Do not wait for symptoms to appear before seeking guidance. If severe symptoms occur, seek emergency medical attention.

Alectinib is used to treat certain types of ALK-positive NSCLC, but it should not be described as a guaranteed cure.

For some patients, treatment may control cancer growth, delay disease progression, or reduce the risk of recurrence in an eligible postoperative setting. Outcomes vary according to the disease, treatment setting, and individual response.

The oncologist can explain the expected treatment goals and how response will be assessed.

The oncology team monitors treatment response through clinical assessments and appropriate imaging examinations. These may include CT or MRI scans, depending on the patient's disease and symptoms.

The doctor may assess:

  • Changes in tumor size.
  • Whether new areas of disease have appeared.
  • Symptoms and physical condition.
  • Treatment tolerance.
  • Laboratory test results.

The frequency of follow-up examinations depends on the individual treatment plan.

No. Patients should not stop alectinib simply because symptoms improve or they feel healthier.

Cancer treatment may need to continue even when symptoms are controlled. Stopping treatment without medical advice may affect disease control.

If a patient experiences side effects, cost concerns, or difficulty taking the medicine, they should discuss the situation with their oncology team before making any changes.

Patients should follow the storage instructions printed on the original Alecnib packaging.

General precautions include keeping the medicine in its original packaging when appropriate, protecting it from unsuitable storage conditions, checking the expiry date, and keeping it away from children.

Do not use expired, damaged, or improperly stored medicine without first asking a pharmacist or healthcare professional.

Both names are associated with alectinib in the information presented here, but that does not establish that the products are identical.

Alecensa is an established reference brand of alectinib. Alecnib is identified on this website as a product with a stated strength of 150 mg. Its manufacturer, regulatory status, formulation, and relationship to other alectinib products must be confirmed through product-specific documentation.

Patients should not assume that different products are interchangeable without confirmation from a qualified healthcare professional.

Yes. Alectinib is intended for cancers with a specific ALK alteration. An appropriate validated diagnostic test is used to identify eligible patients.

A healthcare professional should review the test results and confirm that the patient's cancer meets the relevant treatment criteria before prescribing an ALK inhibitor.

Alectinib is not intended for every patient with NSCLC.

Whether alectinib can be used alongside another cancer treatment depends on the clinical situation. Combining treatments may increase the risk of adverse effects or require a specific treatment sequence.

Patients should not combine alectinib with chemotherapy, radiation therapy, immunotherapy, or another targeted medicine unless the treating oncology team has recommended and supervised that approach.

Before starting alectinib, patients should provide their healthcare professional with accurate information about:

  • Their cancer diagnosis and molecular test results.
  • Previous cancer treatments.
  • Liver and kidney conditions.
  • Heart rate or heart rhythm problems.
  • Muscle disorders or unexplained muscle pain.
  • Breathing or lung conditions.
  • Pregnancy or breastfeeding status.
  • All prescription and non-prescription medicines.
  • Vitamins, supplements, and herbal products.

This information helps the healthcare team evaluate treatment suitability and plan appropriate monitoring.

No. Alectinib is a targeted medicine for specified patients with ALK-positive NSCLC. It is not a general treatment for all lung cancers or all patients with NSCLC.

Treatment selection depends on the cancer's molecular characteristics, disease stage, treatment history, and applicable clinical guidelines.

A qualified oncologist should interpret the diagnostic results and determine whether alectinib is an appropriate option.

Patients should report new, persistent, or worsening symptoms to their healthcare professional. They should not assume that every symptom is harmless or automatically related to the medicine.

Symptoms requiring particular attention include:

  • New or worsening shortness of breath.
  • Persistent cough or fever.
  • Yellowing of the skin or eyes.
  • Dark urine.
  • Severe or unexplained muscle pain.
  • Fainting or significant dizziness.
  • Unusual weakness or signs of anemia.
  • Reduced urine output.